• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Acuren Corporation

    5/9/25 4:14:00 PM ET
    $TIC
    Get the next $TIC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ACUREN CORP

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    00510N102

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00510N102


    1Names of Reporting Persons

    Progeny 3, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    VIRGIN ISLANDS, BRITISH
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    15,000,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    15,000,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.3 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    00510N102


    1Names of Reporting Persons

    Jon Hemingway
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    15,000,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    15,000,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ACUREN CORP
    (b)Address of issuer's principal executive offices:

    14434 Medical Complex Drive, Suite 100, Tomball, Texas, 77377
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Progeny 3, Inc., a Washington corporation (the "Manager"), which serves as the manager of certain accounts (collectively, the "Accounts"), and Jon Hemingway ("Hemingway"), who controls the Manager. The foregoing persons may be referred to hereinafter as the "Reporting Person." Any disclosures herein with respect to persons other than the Reporting Person are made on information and belief after making inquiry to the appropriate party. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended. The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.
    (b)Address or principal business office or, if none, residence:

    5209 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033
    (c)Citizenship:

    Progeny 3, Inc. is organized under the laws of the State of Washington and Hemingway is a United States citizen.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    00510N102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The percentages used in this Schedule 13G are calculated based upon the number of shares of Common Stock issued and outstanding as of as reported in the Company's Form 10-K filed March 27, 2025. The information required by Items 4(a) - (c) is set forth in Rows 5-11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The Reporting Persons do not directly own any Common Stock. Pursuant to investment agreements with the Accounts, the Manager maintains voting and dispositive power with respect to the securities held by the Accounts. Hemingway controls the Manager. Under the rules promulgated by the Securities and Exchange Commission, the Reporting Persons may be deemed to beneficially own the Common Stock. Each Reporting Person hereby disclaims beneficial ownership of the securities covered by this statement.
    (b)Percent of class:

    See cover page
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See cover page

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    See cover page

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2. The Accounts have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Progeny 3, Inc.
     
    Signature:/s/ Chris Hemingway
    Name/Title:Chris Hemingway, Co-Chief Investment Officer
    Date:05/09/2025
     
    Jon Hemingway
     
    Signature:/s/ Chris Hemingway
    Name/Title:Chris Hemingway, as Attorney-in-Fact for Jon Hemingway, Chief Executive Officer
    Date:05/09/2025
    Get the next $TIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TIC

    DatePrice TargetRatingAnalyst
    3/21/2025$13.00Neutral
    UBS
    More analyst ratings

    $TIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acuren Corporation Confirms Date for First Quarter 2025 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of critical asset integrity services, announced today that it intends to release its financial results for the three months ended March 31, 2025, before the market opens on Thursday, May 15, 2025. First Quarter Webcast and Conference Call Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, May 15, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. To listen to the call by telephone, please dial 877-407-0789 or 201-689-8562. Yo

      5/7/25 4:15:00 PM ET
      $TIC
    • Acuren Corporation Announces Results for the Fourth Quarter and Full Year 2024

      - Record full year revenue of $1.1 billion driven by deeper service line penetration with recurring customers, targeted new sales in key markets, and certain pricing initiatives - - Acuren has redomiciled in the U.S. and listed on NYSE American - - Establishes 2025 revenue outlook - Acuren Corporation (NYSE:TIC) ("Acuren" or the "Company"), a leading provider of critical asset integrity services, today reported its financial results for the three months and full year ended December 31, 2024. The presentation of our operating results reflects the Company's acquisition of ASP Acuren Holdings, Inc. ("ASP Acuren" or the "ASP Acuren Acquisition"). The period from July 30, 2024, through Decem

      3/27/25 7:00:00 AM ET
      $TIC
    • Acuren Corporation Confirms Date for Fourth Quarter and Full Year 2024 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of asset integrity services, announced today that it intends to release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, March 27, 2025. Webcast and Conference Call: Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday March 27, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. Additionally, a slide presentation will accompany the conference call. To listen to the call by tel

      3/24/25 7:15:00 AM ET
      $TIC

    $TIC
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Acuren Corporation

      SCHEDULE 13G - ACUREN CORP (0002032966) (Subject)

      5/9/25 4:14:00 PM ET
      $TIC
    • SEC Form 424B3 filed by Acuren Corporation

      424B3 - ACUREN CORP (0002032966) (Filer)

      4/24/25 4:28:55 PM ET
      $TIC
    • Acuren Corporation filed SEC Form 8-K: Other Events

      8-K - ACUREN CORP (0002032966) (Filer)

      4/24/25 4:23:39 PM ET
      $TIC

    $TIC
    Financials

    Live finance-specific insights

    See more
    • Acuren Corporation Confirms Date for First Quarter 2025 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of critical asset integrity services, announced today that it intends to release its financial results for the three months ended March 31, 2025, before the market opens on Thursday, May 15, 2025. First Quarter Webcast and Conference Call Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, May 15, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. To listen to the call by telephone, please dial 877-407-0789 or 201-689-8562. Yo

      5/7/25 4:15:00 PM ET
      $TIC
    • Acuren Corporation Announces Results for the Fourth Quarter and Full Year 2024

      - Record full year revenue of $1.1 billion driven by deeper service line penetration with recurring customers, targeted new sales in key markets, and certain pricing initiatives - - Acuren has redomiciled in the U.S. and listed on NYSE American - - Establishes 2025 revenue outlook - Acuren Corporation (NYSE:TIC) ("Acuren" or the "Company"), a leading provider of critical asset integrity services, today reported its financial results for the three months and full year ended December 31, 2024. The presentation of our operating results reflects the Company's acquisition of ASP Acuren Holdings, Inc. ("ASP Acuren" or the "ASP Acuren Acquisition"). The period from July 30, 2024, through Decem

      3/27/25 7:00:00 AM ET
      $TIC
    • Acuren Corporation Confirms Date for Fourth Quarter and Full Year 2024 Earnings Release

      Acuren Corporation (NYSE:TIC) (the "Company" or "Acuren"), a leading provider of asset integrity services, announced today that it intends to release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, March 27, 2025. Webcast and Conference Call: Acuren will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday March 27, 2025. Participants on the call will include Talman Pizzey, Chief Executive Officer, Kristin Schultes, Chief Financial Officer, and Robert A.E. Franklin, Co-Chairman. Additionally, a slide presentation will accompany the conference call. To listen to the call by tel

      3/24/25 7:15:00 AM ET
      $TIC

    $TIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF HUMAN RESOURCES OFFICER Gaucher Anthony

      4 - ACUREN CORP (0002032966) (Issuer)

      4/15/25 4:36:46 PM ET
      $TIC
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Pizzey Talman

      4 - ACUREN CORP (0002032966) (Issuer)

      4/15/25 4:30:08 PM ET
      $TIC
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Schultes Kristin B

      4 - ACUREN CORP (0002032966) (Issuer)

      4/15/25 4:30:06 PM ET
      $TIC

    $TIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Acuren Corporation with a new price target

      UBS initiated coverage of Acuren Corporation with a rating of Neutral and set a new price target of $13.00

      3/21/25 8:16:22 AM ET
      $TIC